SUPERNUS PHARMACEUTICALS (SUPN) stock: insider trades, news & valuation
Heavy sellingShare price and insider trades
SUPERNUS PHARMACEUTICALS insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 8 sold $14.6M of SUPN stock on the open market.
Get emailed when insiders cluster-buy stocks like SUPN
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
SUPN insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | — | 0 |
| Q2 2026 | — | 0 | — | 0 |
| Q1 2026 | — | 0 | $9.2M | 17 |
| Q4 2025 | — | 0 | $7.4M | 9 |
| Q3 2025 | — | 0 | $414K | 1 |
Valuation, profit and volume
Summary
Over the past 12 months, 0 SUPERNUS PHARMACEUTICALS, INC. insiders reported open-market purchases totaling $0, while 8 insiders reported sales totaling $14.6M. 20 of 27 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Mar 18SEC | Padmanabh P. BhattSr. Vp Of Ip, Cso | Sell Plan | 34,11432,930 held (−51%) | $50.18 | $1.7M | -15.0% | — |
| Mar 18SEC | Padmanabh P. BhattSr. Vp Of Ip, Cso | Sell Plan | 27,71039,334 held (−41%) | $49.95 | $1.4M | -14.6% | — |
| Mar 18SEC | Padmanabh P. BhattSr. Vp Of Ip, Cso | Sell Plan | 22,29017,044 held (−57%) | $50.73 | $1.1M | -15.9% | — |
| Mar 18SEC | Padmanabh P. BhattSr. Vp Of Ip, Cso | Sell Plan | 15,88617,044 held (−48%) | $50.49 | $802K | -15.5% | — |
| Mar 18SEC | Padmanabh P. BhattSr. Vp Of Ip, Cso | Sell Plan | 6,83817,456 held (−28%) | $49.55 | $339K | -13.9% | — |
| Mar 18SEC | Padmanabh P. BhattSr. Vp Of Ip, Cso | Sell Plan | 41217,044 held (−2%) | $50.48 | $21K | -15.5% | — |
| Mar 16SEC | Jack A. KhattarCEO, President | Sell Plan | 24,138968,962 held (−2%) | $50.09 | $1.2M | -14.8% | — |
| Mar 16SEC | Jack A. KhattarCEO, President | Sell Plan | 10,742958,220 held (−1%) | $51.00 | $548K | -16.3% | — |
| Mar 16SEC | Frederick M. HudsonDirector | Sell | 5,36960,413 held (−8%) | $50.61 | $272K | -15.7% | — |
| Mar 16SEC | Jack A. KhattarCEO, President | Sell Plan | 120958,100 held (−0%) | $51.75 | $6K | -17.5% | — |
| Mar 10SEC | William Todd HorichSvp, Commercial Operations | Sell | 4,439 | $55.00 | $244K | -22.4% | — |
| Mar 10SEC | William Todd HorichSvp, Commercial Operations | Sell | 4,4384,439 held (−50%) | $54.00 | $240K | -21.0% | — |
| Mar 10SEC | Frank MottolaSvp, Chief Tech. Ops. Officer | Sell | 1,62318,440 held (−8%) | $53.65 | $87K | -20.5% | — |
| Mar 9SEC | Georges GemayelDirector | Sell | 10,00028,159 held (−26%) | $53.71 | $537K | -20.6% | — |
| Mar 9SEC | Georges GemayelDirector | Sell | 8,78727,277 held (−24%) | $53.00 | $466K | -19.5% | — |
| Feb 23SEC | Bethany SensenigDirector | Sell Plan | 3,258 | $51.27 | $167K | -16.8% | — |
| Feb 23SEC | Bethany SensenigDirector | Sell Plan | 1,2173,258 held (−27%) | $50.31 | $61K | -15.2% | — |
| Dec 22SEC | Frank MottolaSvp, Chief Tech. Ops. Officer | Sell Plan | 15,00015,496 held (−49%) | $50.47 | $757K | -15.5% | — |
| Dec 22SEC | Frank MottolaSvp, Chief Tech. Ops. Officer | Sell Plan | 5,00015,496 held (−24%) | $50.22 | $251K | -15.0% | — |
| Dec 19SEC | Padmanabh P. BhattSr. Vp Of Ip, Cso | Sell | 71014,508 held (−5%) | $44.44 | $32K | -4.0% | — |
| Oct 10SEC | Jack A. KhattarCEO, President | Sell Plan | 58,3711,208,107 held (−5%) | $50.55 | $3.0M | -15.6% | — |
| Oct 10SEC | Charles W Newhall IIIDirector | Sell Plan | 23,800105,844 held (−18%) | $50.73 | $1.2M | -15.9% | — |
| Oct 10SEC | Jack A. KhattarCEO, President | Sell Plan | 1,5291,206,578 held (−0%) | $51.46 | $79K | -17.1% | — |
| Oct 10SEC | Charles W Newhall IIIDirector | Sell Plan | 1,200104,644 held (−1%) | $51.55 | $62K | -17.2% | — |
| Oct 3SEC | Jack A. KhattarCEO, President | Sell Plan | 1,9041,161,233 held (−0%) | $48.06 | $92K | -11.2% | — |
| Oct 2SEC | Jack A. KhattarCEO, President | Sell Plan | 40,1731,160,870 held (−3%) | $48.07 | $1.9M | -11.2% | — |
| Oct 1SEC | Jack A. KhattarCEO, President | Sell Plan | 8,5881,147,258 held (−1%) | $48.25 | $414K | -11.6% | — |
Insiders at SUPERNUS PHARMACEUTICALS, INC.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Jack A. KhattarCEO, President | — | $7.2M | Mar 16, 2026 | — |
| Padmanabh P. BhattSr. Vp Of Ip, Cso | — | $5.4M | Mar 18, 2026 | — |
| Charles W Newhall IIIDirector | — | $1.3M | Oct 10, 2025 | — |
| Frank MottolaSvp, Chief Tech. Ops. Officer | — | $1.1M | Mar 10, 2026 | — |
| Georges GemayelDirector | — | $1.0M | Mar 9, 2026 | — |
| William Todd HorichSvp, Commercial Operations | — | $484K | Mar 10, 2026 | — |
| Frederick M. HudsonDirector | — | $272K | Mar 16, 2026 | — |
| Bethany SensenigDirector | — | $228K | Feb 23, 2026 | — |
SUPN stock: common questions
Are SUPERNUS PHARMACEUTICALS, INC. insiders buying SUPN stock?
In the past 12 months, 0 insiders reported open-market purchases of SUPN worth $0.
Are SUPERNUS PHARMACEUTICALS, INC. insiders selling SUPN stock?
8 insiders reported sales worth $14.6M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is SUPN's 52-week range?
Over the past year SUPN has traded between $41.28 and $57.00. It last closed at $42.67 on Oct 9, 2026.